Cargando…

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation

Despite its common use in nonmyeloablative preparative regimens, the pharmacokinetics of fludarabine are poorly characterized in hematopoietic cell transplantation (HCT) recipients and exposure-response relationships remain undefined. Our objective of this study was to evaluate the association betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long-Boyle, Janel R, Green, Kathleen G.E., Brunstein, Claudio G., Cao, Qing, Rogosheske, John, Weisdorf, Daniel J., Miller, Jeffrey S., Wagner, John E, McGlave, Philip B., Jacobson, Pamala A
Formato:	Texto
Lenguaje:	English
Publicado:	2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904846/ https://www.ncbi.nlm.nih.gov/pubmed/20383215 http://dx.doi.org/10.1038/bmt.2010.53

Ejemplares similares

Factors Predicting Single-Unit Predominance after Double Umbilical Cord Blood Transplantation
por: Ramirez, Pablo, et al.
Publicado: (2011)

Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
por: Paplham, Pamela, et al.
Publicado: (2014)

Higher Therapeutic Cyclosporine Levels Early Post-Transplantation Reduces Risks of Acute Graft-Versus-Host Disease and Improves Survival
por: Rogosheske, John R., et al.
Publicado: (2013)

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome
por: Gross, TG, et al.
Publicado: (1999)

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation
por: Brooks, Jordan T., et al.
Publicado: (2022)

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation
por: Kanda, Junya, et al.
Publicado: (2011)

Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
por: Hegerova, Livia, et al.
Publicado: (2017)

Graft-versus-Leukemia Effect of Nonmyeloablative Stem Cell Transplantation
por: Imamura, Masahiro, et al.
Publicado: (2009)

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients
por: Jaklič, Alenka, et al.
Publicado: (2013)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

National Trends and Outcomes Associated With Presence and Type of Usual Clinician Among Older Adults With Multimorbidity
por: Ganguli, Ishani, et al.
Publicado: (2021)

BEAM Conditioning Is Well Tolerated and Yields Similar Survival in Obese and Non-Obese Patients with Lymphoma: No Requirement for Weight-Based Dose Modifications
por: Fair, Christina, et al.
Publicado: (2017)

Autologous nonmyeloablative hematopoietic stem cell transplantion in newly diagnosed childhood type 1 diabetes mellitus: the first year report
por: Luo, Feihong, et al.
Publicado: (2013)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy
por: Penaforte-Saboia, Jaquellyne G., et al.
Publicado: (2017)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022
por: Nikpay, Sayeh, et al.
Publicado: (2023)

Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation
por: Kim, Nayoun, et al.
Publicado: (2015)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2018)

Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation
por: Elmariah, Hany, et al.
Publicado: (2021)

Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E, et al.
Publicado: (2017)

(GT)(n) Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Køllgaard, Tania, et al.
Publicado: (2016)

Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2020)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
por: Banna, G L, et al.
Publicado: (2006)

Correction: Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E., et al.
Publicado: (2018)

Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report
por: Annaloro, Claudio, et al.
Publicado: (2015)

Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation
por: Toh, H C, et al.
Publicado: (2011)

Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update
por: Erotocritou, P., et al.
Publicado: (2006)

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas
por: Delioukina, Maria, et al.
Publicado: (2011)

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2020)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Transient regulatory T-cell (Treg) depletion with IL-2 diphtheria toxin fusion protein enhances clearance of acute myeloid leukemia by haploidentical natural killer (NK) cells
por: Bachanova, Veronika, et al.
Publicado: (2013)

Infections in Recipients of Hematopoietic Stem Cell Transplants
por: Young, Jo-Anne H., et al.
Publicado: (2015)

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
por: Hamadani, Mehdi, et al.
Publicado: (2020)

A nonmyeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma
por: Yu, K., et al.
Publicado: (2018)

Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
por: Kalwak, Krzysztof, et al.
Publicado: (2020)

Extension of Maximal Lifespan and High Bone Marrow Chimerism After Nonmyeloablative Syngeneic Transplantation of Bone Marrow From Young to Old Mice
por: Kovina, Marina V., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6jlpkn6d9kaaoso99f0g3cjnia